NCT05216120

Pemigatinib in Subjects With Adenosquamous Carcinoma of the Pancreas

Efficacy and Safety of Pemigatinib in Subjects With Advanced Metastatic or Surgically Unresectable Adenosquamous Carcinoma of the Pancreas (ASCP) Who Have Progressed On Previous Therapy

• Status: Withdrawn
• Phase: Phase 2
• Study type: Interventional
• Enrollment: 0 (actual)
• Sponsor: HonorHealth Research Institute · Academic / Other
• Sex: All
• Age: 18 Years – 100 Years
• Healthy volunteers: Not accepted

Summary

The purpose of this research is to determine the benefit of pemigatinib in patients with advanced metastatic or surgically unresectable adenosquamous carcinoma of the pancreas who have progressed on previous therapy.

Conditions

• Pancreas Cancer

Interventions

Type	Name	Description
DRUG	Pemigatinib 4.5 MG	Pemigatinib 4.5 mg tablets taken 3 times per day \[daily dose of 13.5 mg (3 tablets)\] for 14 consecutive days followed by 7 days off medication in 21-day cycles Doses will be self-administered at home. Participants will be instructed to take study medication at the same time each day, with or without food.

Timeline

• Start date: 2022-06-14
• Primary completion: 2024-08-31
• Completion: 2025-08-31
• First posted: 2022-01-31
• Last updated: 2023-07-03

Locations

1 site across 1 country: United States

Regulatory

• FDA-regulated drug study